The key facts
- Isomorphic Labs raised $5 billion in a Series C round; the round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and all previous investors joining
- The company reported 'positive preclinical results' in oncology and immunology and partnerships with Eli Lilly, Novartis, and Johnson & Johnson
- The new valuation was not disclosed; Bloomberg previously reported the round was discussed at a $50 billion valuation
The largest round on the road to the clinic
Isomorphic Labs — a platform for developing drugs with the help of AI, spun out of Google DeepMind in 2021 — has raised $5 billion in a Series C round. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz among the new investors. All previous backers also participated: Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
What the company does and what the money will fund
Isomorphic Labs is building an AI drug design engine based on a set of simulation models that explore different areas of chemistry. The technological foundation is AlphaFold, DeepMind's model for predicting the three-dimensional structure of proteins from genetic sequences; for this work, the company's founder and CEO Demis Hassabis and then-Director of DeepMind John Jumper received the Nobel Prize in Chemistry. According to the company, its program has delivered 'positive preclinical results' in oncology and immunology, and the lab has signed agreements with Eli Lilly, Novartis, and Johnson & Johnson. The new funds will go toward further development of the engine and expansion into other types of medicine — the round follows the $2.1 billion Series B in May.
Valuation and leadership changes
This is the company's first round since Hassabis stepped down as head of DeepMind to focus on drug development, moving to a chairman role at DeepMind. Isomorphic did not disclose its new valuation; earlier this month, Bloomberg reported that the company was seeking funding at a $50 billion valuation — this is information not confirmed by the company.


